Global Neurokinin Receptor Antagonists API Market Growth 2026-2032

The global Neurokinin Receptor Antagonists API market size is predicted to grow from US$ million in 2025 to US$ million in 2032; it is expected to grow at a CAGR of %from 2026 to 2032.

Neurokinin receptor antagonists API (active pharmaceutical ingredient) refers to the biologically active compounds that inhibit the action of neurokinins by blocking their respective receptors, primarily neurokinin-1 (NK1) and neurokinin-3 (NK3) receptors. These antagonists are designed to counteract the effects of neuropeptides such as substance P and neurokinin B, which are involved in various physiological processes, including the regulation of nausea, vomiting, pain perception, and mood.

United States market for Neurokinin Receptor Antagonists API is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.

China market for Neurokinin Receptor Antagonists API is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.

Europe market for Neurokinin Receptor Antagonists API is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.

Global key Neurokinin Receptor Antagonists API players cover Dr. Reddy's Laboratories, Glenmark Life Sciences, Jubilant Pharmova, Murli Krishna Pharma, MSN Laboratories, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.

LP Information, Inc. (LPI) ' newest research report, the “Neurokinin Receptor Antagonists API Industry Forecast” looks at past sales and reviews total world Neurokinin Receptor Antagonists API sales in 2025, providing a comprehensive analysis by region and market sector of projected Neurokinin Receptor Antagonists API sales for 2026 through 2032. With Neurokinin Receptor Antagonists API sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Neurokinin Receptor Antagonists API industry.

This Insight Report provides a comprehensive analysis of the global Neurokinin Receptor Antagonists API landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Neurokinin Receptor Antagonists API portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Neurokinin Receptor Antagonists API market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Neurokinin Receptor Antagonists API and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Neurokinin Receptor Antagonists API.

This report presents a comprehensive overview, market shares, and growth opportunities of Neurokinin Receptor Antagonists API market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:
Fezolinetant
Aprepitant
Rolapitant
Fosaprepitant
Netupitant
Maropitant

Segmentation by Application:
Tablets
Capsules
Oral Suspension
Injections
Other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Dr. Reddy's Laboratories
Glenmark Life Sciences
Jubilant Pharmova
Murli Krishna Pharma
MSN Laboratories
Optimus Pharma
Piramal Pharma
Solara Active Pharma Sciences
Camus Pharma
Clearsynth Labs
Helsinn Advanced Synthesis
Procos
Andenex
Taizhou Crene Biotechnology
Zydus Animal Health And Investments
Wisdom Pharmaceutical
Zhejiang Tiantai Pharmaceutical
Qilu Pharmaceutical
Kelun Pharmaceutical
Hansoh Pharma
Luoxin Pharmaceuticals
Hangzhou Jiuyuan Gene Engineering
Lianyungang Runzhong Pharmaceutical
Viwit
Humanwell Pharmaceutical
Shandong Anxin Pharmaceutical
Beijing Sjar Technology Development
Sichuan Qingmu Pharmaceutical
Shandong New Time Pharmaceutical
United Pharma

Key Questions Addressed in this Report

What is the 10-year outlook for the global Neurokinin Receptor Antagonists API market?

What factors are driving Neurokinin Receptor Antagonists API market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Neurokinin Receptor Antagonists API market opportunities vary by end market size?

How does Neurokinin Receptor Antagonists API break out by Type, by Application?

Please note: The report will take approximately 2 business days to prepare and deliver. Show more